

Aug 2020

NIH-NIDDK



## CAIRIBU COMMUNITY COMMUNIQUE



### Collaborating for the Advancement of Interdisciplinary Research in Benign Urology

#### CAIRIBU MISSION

The CAIRIBU community will foster collaboration across multiple basic science and clinical disciplines to identify and address gaps in knowledge related to the biology, physiology, biochemistry, genomics, genetics, and metabolism of benign urologic diseases. Our overarching goals are to (1) **support the next generation of urologic researchers** by providing meaningful education and mentoring; (2) **enhance knowledge of mechanisms** associated with normal development, function, and disease pathology related to the urinary tract, kidney, and prostate; (3) **cultivate new research tools and ideas** by expanding the collaborative network within and outside of the traditional urologic research field; and (4) use the knowledge and tools generated from our collaborative work to **reduce the burden of benign urologic illness and disability** by developing and testing new therapies to effectively treat, manage, and prevent these diseases. CAIRIBU aims to create a transdisciplinary infrastructure to promote benign urologic research collaborations, encourage and embrace new investigators into the field, train and mentor the next generation of benign urologic basic scientists and clinician scientists, and develop and share resources and new tools to enhance urology research.

#### FUNDING – Early Investigators 2020 SBUR Young Investigator Awards

The **Society for Basic Urologic Research (SBUR)** Young Investigator Awards are given to SBUR members under the age of 45, within five years of their first faculty position, and who have made significant contributions to basic and translational urologic research. Eligible candidates should submit a cover letter highlighting their contributions to urologic research and a CV to [sbur@affinity-strategies.com](mailto:sbur@affinity-strategies.com). The application deadline is August 31, 2020.

#### 2021 Research Scholar Award

Deadline extended!!! With a commitment to continuing their strong support for urologic research, the AUA and its Urology Care Foundation announces that the 2021 **Research Scholar Award** competition is extended to November 5, 2020. Questions about applying to the 2021 program can be directed to [grantsmanager@auanet.org](mailto:grantsmanager@auanet.org).

#### SPECIAL ISSUE – Benign Urology

**UROLOGY** (Gold Journal) is planning a special edition on the **burden of non-malignant genitourinary diseases and disorders**. Guest editors are W. Stuart Reynolds, MD, MPH and Richard Lee, MD, MBA. The purpose of the issue is to raise awareness and highlight the significant impact and burden that benign GU diseases have on individuals, their communities, society, and the healthcare system. Manuscripts on the impact of benign GU conditions on medicine, society, the environment, and the economy are encouraged. Submission deadline is February 1, 2021.

#### CAIRIBU MEETING VIA ZOOM

The 2020 CAIRIBU meeting is now a virtual meeting. It will begin at 12:30 p.m. (Eastern Time) on Thursday, Dec. 3 and conclude after the poster session at 6:30 p.m. On Friday, Dec. 4, the meeting will begin at 10:30 a.m. (Eastern Time) and conclude at 5:30 p.m. The meeting theme is **“Crossing the Disciplinary Divide.”**

In addition to 3 scientific sessions and 3 keynote speakers, a major feature of the 2020 virtual CAIRIBU meeting will be an interactive poster session. **Posters from all CAIRIBU Centers and Programs are anticipated.** See next page for abstract preparation and submission details.

Finally, a **CAIRIBU trainees event is planned for Thursday morning, Dec. 3.** In a recent survey, CAIRIBU trainees identified topics of greatest importance. Stay tuned for details about this trainees session, open to all CAIRIBU-affiliated students, fellows, residents, post-docs, K scholars, and early investigators (assistant level faculty).

#### WHAT IS CAIRIBU?

Go to <https://niddkcairibu.urology.wisc.edu> for more information and links to all CAIRIBU Centers & Programs.


- **George M. O'Brien Urology U54 Cooperative Research Centers:** (1) University of Wisconsin-Madison, (2) Columbia University, and (3) University of Pittsburgh
- **P20 Exploratory Centers for Interdisciplinary Research in Benign Urology:** (1) Harvard University, (2) Columbia University, (3) University of Alabama at Birmingham, (4) NorthShore University HealthSystem/Purdue University, (5) Washington University, (6) Duke University, (7) Vanderbilt University, (8) University of Tennessee, and (9) Albert Einstein College of Medicine
- **K12 Urological Epidemiology Institutional Career Development Programs:** (1) University of Michigan, and (2) University of California San Francisco/Kaiser Permanente
- **K12 Multidisciplinary Urologic Research Career Development Programs:** (1) Duke University, and (2) University of Wisconsin-Madison



Kristina Penniston, Director of Interactions  
[penn@urology.wisc.edu](mailto:penn@urology.wisc.edu) | 608.265.9797  
Tamara Bavendam, Project Scientist  
[tamara.bavendam@nih.gov](mailto:tamara.bavendam@nih.gov)  
Chris Mullins, Program Official  
[mullinsc@extra.niddk.nih.gov](mailto:mullinsc@extra.niddk.nih.gov)

The virtual 2020 CAIRIBU meeting will have a poster session. PDFs of posters will be on “display” throughout the entire CAIRIBU meeting in a “poster room.” During the poster session itself, presenters will take turns giving flash talks (1-2 min each), followed by time for individual discussion with each presenter. **Start preparing your abstracts now!** They are due OCTOBER 1, 2020. Each abstract will be reviewed by at least 2 reviewers with appropriate expertise. Written reviews will be made available at the end of the meeting to each presenter. BEST POSTER AWARDS will be given.

## General abstract guidelines

- 
- All authors named in the abstract must have agreed to its submission for presentation
  - It is the responsibility of the submitting author to ensure the abstract is in perfect order with no spelling or grammatical errors as abstracts will not be corrected
  - Submitted abstracts will be evaluated individually by peer reviewers based on these criteria:
    1. **Context and interest:** Question or hypothesis is clearly stated, key evidence leading to question or hypothesis is clearly articulated, scientific/clinical significance is cited
    2. **Experimental design and data presentation:** Experimental approach and methods are clearly described, data is concisely presented and prioritized to include most relevant findings
    3. **Evaluation and analysis of data:** Results are concisely described, conclusions are clearly noted without over- or under-statement, future work to alleviate any remaining questions is cited, figures and/or tables (if used) are helpful to illustrate findings
    4. **Written communication:** Title is informative, abstract is written well and presented in logical order without irrelevant information, scientific nomenclature is correctly used
  - Abstracts of works “in progress” are acceptable
  - High quality abstracts may be chosen for awards and potentially for oral presentations [*guidelines for oral presentations – e.g., length, # of slides, format, etc. – will be available after the abstract submission deadline*]
  - An author may submit up to 3 abstracts, but only one will be eligible for an oral presentation of any kind

## Preparation of abstracts

1. **Deadline.** Abstracts are due by 11:59 p.m. (Central Time) on October 1, 2020. Send via email (Word doc or PDF) to [penn@urology.wisc.edu](mailto:penn@urology.wisc.edu).
2. **Size.** Abstract is limited to 2,330 characters not including spaces. Character count includes body of abstract, tables, and graphics (i.e., NOT the title, authors’ names or affiliations). Tables account for 225 characters per table. Graphics also account for 225 characters each.
3. **Title.** Should clearly define the topic and contain no abbreviations.
4. **Authors.** List the primary author’s full name followed by other authors’ names. Spell out the names of all authors using full first name, middle initial, and last name. List each author’s affiliation as in the example on the next page.
5. **Body of abstract.** The abstract should be informative and detailed.
  - a. Body must contain 4 separate paragraphs: **Introduction and Objective, Methods, Results, and Conclusions**
  - b. It is not acceptable to state that “results will be discussed;” specific outcomes are necessary, including for abstracts that describe studies still in progress
  - c. Major new findings should be clearly articulated
  - d. Standard abbreviation may be used after spelling out the full term the first time it is used followed by the abbreviation in parenthesis
  - e. Graphs and/or tables may be used; character count is as stated in #1 above
  - f. Proprietary names of drugs are not allowed; use generic names